The many faces of HFPEF: insights from the CMR substudy of DIAMOND-HFPEF by unknown
POSTER PRESENTATION Open Access
The many faces of HFPEF: insights from the CMR
substudy of DIAMOND-HFPEF
Prathap Kanagala1*, Adrian S Cheng2, Anvesha Singh1, Jamal N Khan1, Sheraz A Nazir1, Iain B Squire1, Leong L Ng1
, Gerry P McCann1
From 18th Annual SCMR Scientific Sessions
Nice, France. 4-7 February 2015
Background
Heart failure with preserved ejection fraction (HFPEF)
carries significant mortality and morbidity. This popula-
tion is characterized by marked heterogeneity. To date,
this population has been poorly phenotyped and it
remains unclear what proportion may have evidence of
myocardial infarction (MI), undiagnosed cardiomyopa-
thies or phenocopies of heart failure. At present, echo-
cardiography remains the primary modality for diagnosis
and inclusion into randomized controlled trials but can
be challenging due to the high prevalence of lung dis-
ease, obesity and frailty. We sought to evaluate the
impact of adding cardiac magnetic resonance imaging
(CMR) to the diagnostic pathway.
Methods
CMR was offered as part of DIAMOND-HFPEF (Devel-
oping Imaging And plasMa biOmarkers iN Describing
Heart Failure with Preserved Ejection Fraction): a pro-
spective, observational, cohort study. Inclusion criteria
were: clinical features of HF and left ventricular ejection
fraction (LVEF) > 50% as per echocardiography. Exclu-
sion criteria were: suspected or confirmed cardiomyopa-
thy, pericardial constriction, inability to consent, non-
cardiovascular life expectancy < 6 months, myocardial
infarction in the preceding 6 months, severe valve dis-
ease, severe obstructive pulmonary disease (or FEV1 <
30% or FVC < 50% predicted) and estimated glomerular
filtration rate < 30 ml/min/m2. 138 eligible subjects
underwent 3 T CMR (Siemens Skyra) according to a
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Table 1 Baseline Clinical and CMR Characteristics
Age (years) 74 ± 10 BMI (kg/m2) 33 ± 8
Male (n, %) 73 (54) BMI > 35 kg/m2 (n,%) 46 (34)
Sinus Rhythm (n, %) 90 (67) NYHA class (n, %)
Atrial Fibrillation/Flutter (n, %) 44 (33) I: 38 (16)
Heart Rate (bpm) 70 II: 51 (40)
Systolic BP (mmHg) 143 III: 41 (31)
Diastolic BP (mmHg) 73 IV: 4 (3)
Diabetes (n, %) 71 (53) BNP (pg/ml); (median, IQR) 182.3 (166.2, 286.0)
Hypertension (n, %) 125 (93) Serum Creatinine (µmol/l) 102 ± 34
Coronary Artery Disease (n, %) 27 (20) LVEF (%) 57 ± 10
Angina (n, %) 26 (19) LVEDVI (ml/m2) 76 ± 26
COPD/Asthma (n, %) 20/6 (15/4) LVESVI (ml/m2) 33 ± 14
bpm = Beats per minute ; BP = Blood Pressure ; COPD = Chronic Obstructive Pulmonary Disease ; BMI = Body Mass Index ; NYHA = New York Heart Association ;
BNP = Brain Natriuretic Peptide ; IQR = Inter-Quartile Range ; LVEF = Left Ventricular Ejection Fraction ; LVEDVI = Left Ventricular End Diastolic Volume Index ;
LVESVI = Left Ventricular End Systolic Volume Index
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standardized protocol including cine, first-pass perfusion
and late gadolinium imaging. The clinical CMR reports
were made available to patients’ responsible physicians.
Results
Baseline clinical and CMR data are summarized in Table
1. Qualitative analyses revealed new diagnoses of (see
Figure 1): ‘silent’ myocardial infarction (n = 13), hyper-
trophic cardiomyopathy (definite [n = 4], probable [3],
possible [n =1]), pericardial constriction (n = 5) and
amyloid (n = 2). Perfusion imaging revealed reversible
inducible ischaemia in 27 patients, of which 11 were
likely to be secondary to microvascular dysfunction.
Late gadolinium imaging revealed mid-wall focal fibrosis
in 33 patients and insertion point fibrosis in 24 patients.
Conclusions
CMR provides unique insights into etiology, enabling
disease-specific management and the potential for tai-
lored therapies to improve outcomes in HFPEF. Further-
more, the frequent finding of HFPEF ‘phenocopies’ such
as hypertrophic cardiomyopathy and amyloid in our
cohort may in part explain the limited efficacy of gen-
eric medical therapies in numerous randomized con-
trolled studies.
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Figure 1 Examples of new diagnoses based on CMR. A) Late gadolinium imaging illustrating the hallmarks of cardiac amyloid - diffuse
enhancement of the LV and atrial myocardium, dilated atria and pleural & pericardial effusions B) end-diastolic steady state free precession
image of a patient with marked asymmetrical septal hypertrophy C) Late gadolinium imaging demonstrating thickened pericardium with
contrast enhancement in a case of pericardial constriction D) Late gadolinium imaging demonstrating a small sub-endocardial apical lateral
myocardial infarct of 50%-75% transmurality
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